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Background: Acacia catechu (Mimosa family) stem bark extracts have been used traditionally as a dietary
supplement as well as a folk medicine given its reported anti-inflammatory, immunomodulatory, hepatoprotective,
antioxidant, anti-microbial and anti-tumor activities. The present study was undertaken to evaluate the anti-HIV-1
activity of the extracts from stem bark of A. catechu.
Methods: The aqueous and 50% ethanolic extracts of A. catechu stem bark were prepared and 50% ethanolic
extract was further fractioned by successively partitioning with petroleum ether, chloroform and n-butanol. All the
extracts and fractions were evaluated for cytotoxicity and anti-HIV-1 activity using different in vitro assays. The active
n-butanol fraction was evaluated for its inhibition against HIV-1 reverse transcriptase, integrase, protease, pro-viral
genome integration and viral Tat protein mediated transactivation. The effect of n-butanol fraction on the induction
of pro-inflammatory cytokines secretion in Vk2/E6E7 cells and transepithelial resistance in Caco-2 and HEC-1A cells
was investigated.
Results: The aqueous and 50% ethanolic extracts of A. catechu showed IC50 values of 1.8 ± 0.18 μg/ml and
3.6 ± 0.31 μg/ml, respectively in cell-free virus based assay using TZM-bl cells and HIV-1NL4.3 (X-4 tropic). In the
above assay, n-butanol fraction exhibited anti-HIV-1 activity with an IC50 of 1.7 ± 0.12 μg/ml. The n-butanol fraction
showed a dose-dependent inhibition against HIV-1NL4.3 infection of the peripheral blood lymphocytes and against
HIV-1BaL(R-5-tropic) as well as two different primary viral isolates of HIV-1 infection of TZM-bl cells. The n-butanol
fraction demonstrates a potent inhibitory activity against the viral protease (IC50 = 12.9 μg/ml), but not reverse
transcriptase or integrase. Further, in Alu-PCR no effect on viral integration was observed. The n-butanol fraction
interfered with the Tat-mediated Long Terminal Repeat transactivation in TZM-bl cells, mRNA quantitation
(qRT-PCR) and electrophoretic mobility shift assay (EMSA). The n-butanol fraction did not cause an enhanced
secretion of pro-inflammatory cytokines in Vk2/E6E7 cells. Additionally, no adverse effects were observed to the
monolayer formed by the Caco-2 and HEC-1A epithelial cells.
Conclusions: The results presented here show a potential anti-HIV-1 activity of A. catechu mediated by the
inhibition of the functions of the viral protein and Tat.* Correspondence: skgupta@nii.ac.in
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Table 1 Cytotoxicity and anti-HIV-1 activity of the
extracts/n-butanol fraction of stem bark of A. catechu
using HIVNL4.3 in TZM-bl cells based assay
Treatment group TZM-bl cells (μg/ml)
*CC50 *IC50 TI
50% Ethanolic extract 371.0 ±11.7 3.6 ± 0.31 103.0 ± 6.3
Aqueous extract >400** 1.8 ± 0.18 >200
n-Butanol fraction >400** 1.7 ± 0.12 >200
*CC50: The cytotoxic concentration of the extracts/n-butanol fraction that caused
the reduction of viable cells by 50%. All data presented are averages of three
independent experiments done in duplicates (mean ± standard error).
*IC50: The concentration of the extracts/n-butanol fraction that resulted in 50%
inhibition in HIV-1 infection. All data presented are averages of three independent
experiments done in duplicates (mean ± standard error).
**CC50 was not obtained as there was no toxicity up to the maximum
concentration tested.
TI: Therapeutic index is CC50/IC50.
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Highly active antiretroviral therapy (HAART) has led to a
dramatic increase in the longevity and the quality of life
for people infected with HIV-1 [1], but due to the emer-
gence of drug resistant virus [2], there is a continuous
need to develop new anti-HIV-1 agents with novel tar-
gets and mechanisms of action. Topical application of
micobicides not only prevents the viral infection at the
portal of entry but also may empower women with deci-
sion making. Since natural products have an enormous
structural diversity and provide a large reservoir for
new therapeutic/preventive regimens, exploring them
for the targets against HIV-1 infection is a promising
option [3-6].
The early events in HIV-1 life-cycle comprise of the
viral attachment to the host cell surface followed by the
conversion of the viral RNA genome into proviral DNA
by the virally-encoded enzyme, reverse transcriptase (RT),
and its integration in the host genome by the virally-
encoded enzyme integrase [7,8]. The provirus integrated
in the host genome may remain in a quiescent state in the
resting lymphocytes until basal transcription produces a
threshold level of the viral trans-activator protein, Tat. As
Tat accumulates above the threshold, it leads to the tran-
sition from latent state of HIV-1 to active replication
in lymphocytes when the protein interacts with the Tat-
responsive element (TAR) located in the long terminal re-
peat (LTR) promoter in the viral DNA [9-11]. Extracellular
Tat has also been implicated in acquired immunodefi-
ciency syndrome (AIDS) and AIDS-associated pathologies
[12]. The late events of the viral life cycle include the pro-
cesses of HIV-1 mRNA synthesis, protein expression and
virus maturation. The progeny viruses expressed from the
activated viral gene expression are assembled on and bud-
ded through the host cell membrane after being processed
by the viral encoded enzyme protease [7]. Compounds
that block activation or suppression of the viral gene
expression have a therapeutic potential for extension of
latency or inhibition of persistent progressive infection.
Discovering drugs that interfere with the functionality of
the crucial enzymes of HIV-1 that play a critical role in
viral pathogenesis i.e. RT, integrase and protease are im-
portant targets to be considered against HIV-1 infection.
Acacia catechu, commonly known as catechu, cachou
and black cutch is an important medicinal plant, especially
prevalent in Asia. It is an extensively studied plant. A wide
spectrum of compounds that have been isolated and cha-
racterized from A. catechu include 4-hydroxybenzoic acid,
kaempferol, quercetin, 3,4',7-trihydroxyl-3′,5-dimethoxy-
flavone, catechin, rutin, isorhamnetin, epicatechin, afze-
lechin, epiafzelechin, mesquitol, ophioglonin, aromadendrin
and phenol [13]. Catechins, rutin and isorhamnetin ex-
hibit antioxidant property by scavenging free-radicals [14].
The flavonoid rich extract of A. catechu mainly comprisedof catechins demonstrated anti-inflammatory activity by
reducing the production of pro-inflammatory eicosanoids
[15] as well as immunomodulatory property with a sig-
nificant effect on cell mediated and humoral immunity
against foreign antigens [16,17]. The methanolic extract
of this plant possesses antimicrobial activity against dif-
ferent species of pathogenic and non-pathogenic micro-
organisms [18] as well as DNA protective activities [19].
Anti-fertility activity of a traditional contraceptive pill
comprising A. catechu has also been reported [20].
In context of the ethnopharmacological importance of
A. catechu, we screened its aqueous and ethanolic extracts
for anti-HIV-1 activity. Further, the active n-butanol frac-
tion was studied for its ability to block HIV-1 infection
and the possible mechanisms of action.
Results
Cytotoxicity and anti-HIV-1 activity of extracts, fractions
and compounds from A. catechu
Our interest was to systematically evaluate aqueous
and 50% ethanolic extracts prepared from stem bark of
A. catechu for activity against HIV-1 after their initial
characterization. Multiple peaks were observed in the
reverse phase HPLC profiles of both aqueous as well as
50% ethanolic extracts of A. catechu stem bark, at an
isocratic gradient (Additional file 1: Figure S1). The 50%
ethanolic extract appeared to be more complex as com-
pared to that of aqueous extract. The initial screening
for anti-HIV-1 activity of the A. catechu extracts was
performed using reporter-gene based TZM-bl cells.
Extracts were first screened for their impact on cellular
viability. CC50 is the concentration of the extracts that
reduced the cell viability by 50%. The 50% ethanolic
extract showed CC50 at 371.0 ± 11.7 μg/ml whereas the
aqueous extract was non-toxic up to 400 μg/ml for
TZM-bl cells (Table 1). A dose-dependent inhibition in
HIV-1NL4.3 infection by the aqueous as well as 50%
ethanolic extracts was observed (Figure 1). The 50%
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Figure 1 Anti-HIV-1 activity of Acacia catechu extracts. TZM-bl cells were infected with HIV-1NL4.3 (MOI, 0.05) pretreated for 1 h with extracts
prepared from A. catechu and incubated for 48 h in the presence or absence of extracts as described in Materials and Methods. Anti-HIV-1 activity
at varying concentrations of the 50% ethanolic, aqueous stem bark extracts and AZT (1 μM), used as a positive reference control, has been
shown. Y-axis represents the percent inhibition of HIV-1 infection. Values are expressed as mean ± SE of 3 different experiments performed in
duplicates. *p < 0.05; **p < 0.001 (as compared to infected control group without any treatment).
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http://www.virologyj.com/content/10/1/309inhibitory concentrations (IC50) of the 50% ethanolic and
aqueous extracts were 3.6 ± 0.31 and 1.8 ± 0.18 μg/ml,
respectively (Table 1).
Of the three fractions, petroleum ether, chloroform and
n-butanol soluble fractions prepared from the 50%
ethanolic extract of stem bark, HPLC profiles suggest the
chloroform fraction to be the most complex, with ma-
ximum number of peaks (Additional file 2: Figure S2).
However, the n-butanol fraction demonstrated better cell
viability and anti-HIV-1 activity. There was no toxicity
observed by the n-butanol fraction up to a maximum con-
centration of 400 μg/ml on TZM-bl cells (Table 1). A
dose-dependent inhibition was observed with an IC50
value of 1.7 ± 0.12 μg/ml using TZM-bl cell based assay
(Figure 2A; Table 1). Further, the n-butanol fraction
exhibited a marked decrease in HIV-1BaL (R-5 tropic)
infection, at non-cytotoxic concentrations in TZM-bl cells
(Figure 2B). The activity of n-butanol fraction was also
evaluated against two primary isolates of CCR5-tropic
HIV-1 (11IN1290SJ & 17MT14), where potent inhibition
was also observed against both the isolates (Figure 3).
Further, to confirm the efficacy of the n-butanol fraction
of A. catechu in primary cells, PHA-P activated human
peripheral blood lymphocytes (PBLs) based assay was
used. The n-butanol fraction (100 μg/ml) reduced the p24
concentration to 417 pg/ml as compared to 1525 pg/ml in
control (infected PBLs without any treatment; Figure 4A)
i.e. 73% inhibition in HIV-1 infection (Figure 4B). Anti-
HIV-1 activity of the n-butanol fraction in human PBLs
was not due to non-specific cytotoxicity as more than 80%
cells were viable when fraction was used at 100 μg/ml
(Additional file 3: Figure S3). In an initial attempt, to
isolate and characterize pure compounds responsiblefor anti-HIV-1 activity, five different compounds were
purified and screened for their anti-HIV-1 activity using
TZM-bl cells in cell-free virus based assay against HIV-
1NL4.3 (Table 2). Among these compounds, only cate-
chins exhibited a potent anti-HIV-1 activity with CC50
and IC50 values of 950 μg/ml and 0.6 μg/ml, respec-
tively. Investigations for further identification of other
anti-HIV-1 active compounds from the 50% ethanolic
extract of stem bark are under progress.
Probable mechanism of action of the active fraction of
A. catechu
Further studies were performed to delineate the mecha-
nisms by which the extracts/n-butanol fraction prepared
from A. catechu inhibited HIV-1 infection. The inhi-
bition by active n-butanol fraction against HIV-1 entry
and inhibition of the HIV-1 enzymes; RT, integrase and
protease were tested. The active fraction did not show
any inhibition of HIV-1NL4.3 entering into the host cells
(TZM-bl) even at a dosage of 50 μg/ml, when compared
with the known entry inhibitor Bicyclam, which was
95% effective even at 0.4 μg/ml (data not shown). In
cell-based fusion assay that mimic the gp120-CD4-
mediated fusion [21], pre-treatment of HL2/3 cells (ex-
pressing HIV-1 Env on their surface and Tat protein in
cytoplasm) with n-butanol fraction (10 μg/ml) did not
lead to any significant inhibition in fusion with TZM-bl
cells as determined by estimation of luciferase expres-
sion (Additional file 4: Figure S4a). We next determined
whether the n-butanol fraction directly inhibited HIV-1
RT activity. Nevirapine (1 μM), a potent RT inhibitor,
inhibited HIV-1 RT activity by 72%; however, n-butanol
fraction did not show any effect on the RT activity
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Figure 2 Anti-HIV-1 activity of n-butanol fraction of Acacia catechu. A) Anti-HIV-1NL4.3 activity of n-butanol soluble fraction at different
concentrations in TZM-bl cells. B) Inhibition against HIV-1BaL infection using TZM-bl cells. Y-axis represents the luciferase expression in terms of
relative luminescence unit (RLU) in HIV-1 infected and treated TZM-bl cells whereas X-axis represents different concentrations of the butanol
fraction. Values are expressed as mean ± SE of 3 different experiments performed in duplicates. *p < 0.05; **p < 0.001 (as compared to infected
control group without any treatment).
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http://www.virologyj.com/content/10/1/309(Additional file 4: Figure S4b). These results imply that
inhibition of HIV-1 replication by the n-butanol fraction
was not due to its effects on the RT activity but on other
steps of HIV-1 life cycle. To evaluate the effect of
n-butanol fraction on HIV-1 integrase, sodium azide
(0.1%) was used as a reference control that exhibited >90%
inhibition against HIV-1 integrase activity whereas the
n-butanol fraction (50 μg/ml) did not show any signifi-
cant inhibition of integrase activity (Additional file 4:
Figure S4c). The lack of effect on viral integration was
confirmed by treating TZM-bl cells infected with HIV-
1NL4.3, with either the n-butanol fraction or vehicle con-
trol. Viral integration was monitored by Alu-LTR PCR
(Figure 5). As compared to the positive reference con-
trol Raltegravir (10 μM; a HIV-1 integrase inhibitor),
there was no effect of the n-butanol fraction on the
virus integration.Finally, the effect of the n-butanol fraction was eva-
luated on HIV-1 protease activity. The n-butanol frac-
tion showed a significant reduction in HIV-1 protease
activity with an IC50 value of 12.9 μg/ml (Figure 6A).
The standard HIV-1 protease inhibitor drug, Saquinavir
(1 μM) was used as a reference control that showed
100% inhibition. To validate the effect of active fraction
on HIV-1 protease activity, release of mature viral parti-
cles by HIV-1 infected and extract treated PBLs was in-
vestigated. The culture supernatant was used to infect
TZM-bl cells to quantify the infectivity of the released
virions and hence correlate it with the HIV-1 protease
activity. As compared with the culture supernatant
obtained from untreated PBLs there was a decrease in
the expression of luciferase when culture supernatant
from PBL treated with n-butanol fraction was used
(Figure 6B). Similar results were observed with the
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Figure 3 Anti-HIV-1 activity of n-butanol fraction of Acacia catechu against CCR5-tropic clinical isolates. Anti-HIV-1 activity of n-butanol
soluble fraction of A. catechu tested at two different concentrations/AZT (10 μM) against clinical isolates namely HIV-111IN1290SJ and HIV-117MT14, using
TZM-bl cells. Y-axis represents the luciferase expression as RLU in HIV-1 infected and treated TZM-bl cells. Values are expressed as mean ± SE of 3
different experiments performed in duplicate. *p < 0.05; **p < 0.01 (as compared to infected control group without any treatment).
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http://www.virologyj.com/content/10/1/309culture supernatant from HIV-1 infected PBL but
treated with Saquinavir (Figure 6B).
To evaluate the inhibitory effect of extract/fraction on
Tat mediated transactivation of HIV-1 gene expression,
TZM-bl cells were transfected with pcDNA-Tat expres-
sion vector. In TZM-bl cells, luciferase reporter gene is
under the control of LTR promoter and hence Tat-LTR
mediated transactivation was determined by luciferase ex-
pression. The n-butanol fraction prepared from A. catechu
stem bark showed a modest dose-dependent inhibition in
luciferase expression (Figure 7A). Simultaneously, to see
the reduction at mRNA level of luciferase gene (expres-
sion is under the control of Tat-LTR mediated activation),
as a result of treatment of pcDNA-Tat transfected TZM-bl
cells with n-butanol fraction, real-time PCR was per-
formed as described in Materials and Methods. As
expected, there was a dose dependent reduction in the
level of luciferase mRNA in n-butanol fraction treated
transfected cells when compared to untreated transfected
cells (Figure 7B). Further in the Tat-EMSA, no bands were
observed in Lane 1 (in presence of 50 μg/ml of n-butanol
fraction) as compared to Lane 2 where bands appeared as
a result of nuclear Tat protein interaction with DNA
probe. These results demonstrated that the phytochemi-
cals present in the stem bark n-butanol fraction interferes
with the Tat-LTR interaction mediated transactivation
of viral genes in addition to HIV-1 protease activity
(Figure 7C).Preclinical safety study of n-butanol fraction of A. catechu
As an attempt to evaluate the toxic effect of extracts/frac-
tion on vaginal keratinocytes Vk2/E6E7, MTT assay was
used. No cytotoxicity was observed up to 100 μg/ml, by
the extracts and the n-butanol fraction prepared from
A. catechu (data not shown). Further to assess the adverse
effect of these extracts/fraction on pro-inflammatory cyto-
kine secretion, compared to the control, both the plant
extracts as well as n-butanol fraction at 100 μg/ml did not
lead to any increase in the secretion of IL-8. However, a
substantial decrease in its secretion was observed by 50%
ethanolic extract and n-butanol fraction of A. catechu
(Table 3). A decreased secretion of IL-6 was also observed
in case of cells treated with 50% ethanolic stem bark
extract (34.8 pg/ml) and its n-butanol fraction (8.8 pg/ml)
as compared to control value (118.0 pg/ml; Table 3). How-
ever, no change in the secretion of IL-1β and TNF by vagi-
nal keratinocytes was observed with any of the treatment
group at 100 μg/ml (Table 3).
Measurement of transepithelial resistance (TER) has
been done on the tight junctions formed by epithelial cells
such as Caco-2, HEC-1A and MDCK-1 [22]. Nonoxynol-9
(N-9) originally developed as a spermicidal, with activity
against sexually transmitted pathogens including HIV-1
led to epithelial disruption as well as toxicity to the rectal
mucosa as reported by different studies, and hence was
included as a positive control in this work [23]. The
n-butanol fraction of A. catechu was non-toxic on both
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Figure 4 Anti-HIV-1 activity of n-butanol fraction of Acacia catechu using human peripheral blood lymphocytes (PBLs). A) Anti-viral
effect of the n-butanol fraction using peripheral blood lymphocytes (PBLs) against HIV-1NL4.3. PHA-P activated PBLs were infected with virus and were
treated with different concentration of n-butanol fraction from A. catechu. p24 was estimated on 5th day in the culture supernatant. Significance
(p-value) was calculated by comparison with amount of p24 in the infected control group. B) The amount of p24 secreted by infected PBLs in term of
percent inhibition presented on the Y-axis. Values are expressed as mean ± SE of 3 different experiments. *p < 0.05; **p < 0.001 (as compared to
infected control group without any treatment).
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(data not shown). After application of the n-butanol frac-
tion to the apical monolayer of Caco-2 cells (Figure 8A)
and HEC-1A cells (Figure 8B), there was no measurable
effect on TER as shown by the consistency of the treated
monolayer as compared to the untreated control.
Discussion
A. catechu is commonly known as Mimosa catechu,
whose phytoconstituents possess several pharmacological
properties [15,18,24,25]. A. catechu, a medicinally and
economically important plant, may serve as novel source
of anti-HIV-1 active compounds. Although, anti-HIV-1
activity has been reported previously from different spe-
cies of the genus Acacia e.g. Acacia confusa [26], no suchactivity has been shown from A. catechu. Our interest was
to systematically evaluate aqueous and alcohol extracts of
A. catechu for activity against HIV-1. Both the extracts
exhibited a dose-dependent inhibition of HIV-1 infection
at concentrations ranging from 0.1-10 μg/ml against HIV-
1NL4.3. Therapeutic indices (TI) of the 50% ethanolic and
aqueous extracts prepared from stem bark were calculated
as the ratio of CC50 to IC50. A TI of >100 by these extracts
suggest the plant as a candidate for further evaluation
(Table 1). Further, 50% ethanolic extract was partitioned
to yield petroleum ether, chloroform and n-butanol solu-
ble fractions. Out of the three fractions, the n-butanol
fraction demonstrated better anti-HIV-1 potential. Fur-
ther, the n-butanol fraction exhibited a marked decrease
in HIV-1 infection by HIV-1BaL (R-5 tropic) as well as
Table 2 Different compounds isolated from 50%
ethanolic stem bark extract of Acacia catechu
Compounds Anti-HIV-1
activity
Physical
aspect
Chemical Family
Catechins CC50 = 950 μg/ml White powder Flavonoids;
(+)-catechin; & (−)-
epicatechin (cis)IC50 = 0.60 μg/ml
Kaempferol No Yellow
crystalline
powder
Flavonoid
Rutin No Yellow
powder
Flavonoid
glycoside
Ferulic acid No Yellow-white
crystalline
powder
Polyphenol
Caeffic acid No Yellow
powder
Polyphenol
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http://www.virologyj.com/content/10/1/309displayed a potent inhibition of infection of primary iso-
lates of CCR5-tropic HIV-1 at non-cytotoxic concentra-
tions. In an attempt to identify the active compounds
from stem bark of A. catechu responsible for anti-HIV-1
activity, a total of 6 compounds from 50% ethanolic
extract, were isolated and characterized using different
chromatographic and spectroscopic studies (Table 2). Dif-
ferent compounds like catechins, kaempferol, rutin, ferulic
acid and caeffic acid have been isolated and characterized
from A. catechu, among which catechins have shown a
very potent anti-HIV-1 activity in its preliminary studies.
Other compounds, however failed to inhibit HIV-1 infec-
tion in cell-free virus based assay (data not shown). In
previous studies, catechins, epicatechin, epicatechin-3-O-
gallate and epigallocatechin-3-O-gallate were reported as
the predominant compounds present in A. catechu [27].1 2 3
1000 bp
500/517 bp
100 bp
Figure 5 Effect of n-butanol fraction prepared from A. catechu on inte
with HIV-1NL4.3 (MOI, 0.05) pretreated for 1 h with n-butanol fraction prepar
positive reference control and incubated for 48 h in the presence or absen
48 h, cells were trypsinized and washed. Genomic DNA was isolated from H
and viral integration was monitored by Alu-LTR-PCR with Alu-gag primers aIn different investigations by several other groups, cate-
chins isolated from tea leaves have been reported to in-
hibit HIV-1 infection [28,29].
In an attempt, to explore the mode of inhibition of
HIV-1 infection by the active fraction of A. catechu, dif-
ferent in vitro assays were performed. The n-butanol
fraction failed to inhibit the viral entry to the host cells.
Due to the essential role of HIV-1 RT in synthesizing
the double-stranded proviral DNA from single-stranded
HIV-1 RNA genome, it is a major target among the
current anti-HIV-1 therapies. The n-butanol fraction did
not exhibit inhibitory activity against RT enzyme. Fur-
ther, the activity of the n-butanol fraction was assessed
against HIV-1 integrase, an enzyme that leads to the in-
tegration of the reverse transcribed viral DNA into the
genome of the cell and hence plays an essential role in
HIV-1 replication. The n-butanol fraction showed no
adverse effect on this enzyme activity. Suppression of
HIV-1 infection by n-butanol fraction was not at the
pre-integration or integration steps, which was con-
firmed by Alu-LTR PCR where the active extract did not
inhibit integration of viral genome into host DNA.
Hence, the inhibitory effect of n-butanol fraction may be
at the post-integration stage.
HIV-1 protease, an aspartyl protease, is another crucial
enzyme essential for the life cycle of HIV-1, as it cleaves
newly synthesized poly-proteins to create the mature pro-
tein components of an infectious HIV-1 virion. Protease
inhibitors bind to the active site of the viral protease
enzyme, preventing the processing of viral particles into
mature and functional form. Interestingly, the n-butanol
fraction of A. catechu showed a potent inhibition of HIV-1
protease activity. This finding was further supported byIntegrated HIV-1 DNA
Alu-nested PCR
GAPDH
4 5
gration of HIV-1 genome in host cells. TZM-bl cells were infected
ed from A. catechu (50 μg/ml) and Raltegravir (10 μM), used as a
ce of extract/Raltegravir as described in Materials and Methods. After
IV-uninfected/infected cells. DNA (200 ng) was used as a template
nd GAPDH was used as internal control.
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Figure 6 Effect of n-butanol fraction of A. catechu on HIV-1 protease activity and maturation of virion particles. A) Dose dependent
inhibition in HIV-1 protease activity by the n-butanol fraction as compared with Saquinavir used as a reference control in a commercial ELISA kit.
**p < 0.01 (as compared to enzyme only control). B) Comparison of the infectivity of TZM-bl cells by the virions released from the infected and
n-butanol fraction/Saquinavir (a protease inhibitor) treated PBLs. The culture supernatant collected on 5th day was used to infect TZM-bl cells for
48 hours and relative luminescence unit (RLU) was calculated by lysing the cells as described in Materials and Methods. Y-axis represents the
luciferase expression as RLU. Values are expressed as mean ± SE of 2 different experiments performed in duplicate. **p < 0.01 (as compared to
cells treated with soup from infected control group without any treatment).
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http://www.virologyj.com/content/10/1/309the observations that there was a decrease in the release of
mature viral particles by infected PBLs after treatment
with the n-butanol fraction as shown by reduction of
greater than 50% infectious virus in the TZM-bl assay.
Catechins containing galloyl moieties from different plant
sources have been reported to target several key proteins
of HIV-1. Hence, they may inhibit sexual transmission of
HIV-1 by interfering with HIV-1 protease activities [30].
Viral Tat protein plays a pivotal role in both the HIV-1
replication cycle and the pathogenesis of HIV-1 infection[31-33]. HIV-1 Tat protein transactivate HIV-1 LTR pro-
moter by binding to the nascent RNA stem-loop structure
known as the transactivator response region (TAR). It has
also been shown to bind to NFκB enhancer sequence [33].
Hence, inhibiting Tat-mediated functions could be an-
other critical step of intervention by A. catechu. Transfec-
tion of TZM-bl cells with pTat expression vector wherein
luciferase expression is under the control Tat-LTR media-
ted activation, followed by n-butanol fraction treatment
resulted in dose-dependent suppression of luciferase
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Figure 7 (See legend on next page.)
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Figure 7 Study of mechanism of action of the n-butanol fraction of Acacia catechu. A) Inhibitory activity of n-butanol fraction against
Tat-mediated HIV-1 genes transactivation by pTat transfection in TZM-bl cells. Values are expressed as average of 2 different experiments performed in
duplicates. B) The effect of n-butanol fraction on luciferase gene expression at mRNA level. The n-butanol fraction prepared from 50% ethanolic
extract of stem bark of A. catechu was added to TZM-bl cells post-transfection with pTat. Reduction in the expression of luciferase gene was validated
by qRT-PCR. qRT-PCR data is expressed as fold change in expression as compared to control. Values are expressed as mean ± SE of 2 different
experiments performed in duplicate. C) The inhibitory activity of n-butanol fraction using Tat based Electrophoretic Mobility Shift Assay (EMSA). Tat
protein was incubated with DNA probe in presence or absence of the active n-butanol fraction of the plant. Samples were run in 6% non-denaturing
polyacrylamide gel. Lane 1 is with Tat transcription factor (TF) DNA probe + Tat protein (nuclear extract prepared from transfected TZM-bl cells) +
n-butanol fraction (50 μg/ml); Lane 2, TF DNA probe + Tat protein; Lane 3, TF DNA probe only; Lane 4 - TF DNA probe + Cold TF DNA
probe + Tat protein.
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http://www.virologyj.com/content/10/1/309expression. This observation was further corroborated by
the expression level of luciferase mRNA using qRT-PCR.
The inhibition of Tat and LTR interaction was also
confirmed by the Tat-EMSA experiment. Several plant-
derived compounds such as quinolines as well as stilbene-
and purine-derivatives have been reported before to
illustrate anti-HIV-1 activity by inhibiting Tat-LTR inter-
actions [31]. Our unpredicted finding that A. catechu stem
bark has a dual inhibitory mechanism demonstrates that
herbal drugs can be developed that simultaneously in-
hibits HIV-1 protease as well as Tat-LTR mediated HIV-1
transcription.
The effect of these extracts/n-butanol fractions on vagi-
nal keratinocytes viability is highly relevant, if the active
fraction is considered as a topical agent that may be ap-
plied for prevention of HIV-1 transmission (microbicides),
as vaginal epithelial cells form part of the physical barrier
that may impede the passage of cell-free or cell-associated
HIV-1 into sub-epithelial tissues. An effective vaginal mi-
crobicide should also obviate pro-inflammatory responses
that facilitate transepithelial viral penetration and its repli-
cation. Pro-inflammatory cytokines such as IL-1β, IL-6,
IL-8 and TNF stimulate viral replication in latently
infected cells and hence may constitute a considerable
inducible HIV-1 reservoir in the genital secretions [34].
Therefore, it was important to rule out induction of
inflammatory cytokines secretion after application of the
plant extracts/n-butanol fraction on vaginal keratinocytes.Table 3 Pro-inflammatory cytokines secretion by vaginal
keratinocytes after treatment for 24 h with extracts/
n-butanol fraction prepared from stem bark of A. catechu
Treatment with
plant extract/fraction*
Level of cytokines (pg/ml)
IL-8 IL-1β IL-6 TNF
Control 282 ± 5.3 2.2 ± 0.2 118 ± 9.1 1.1 ± 0.6
Aqueous extract 248 ± 11.1 3.4 ± 0.2 115.0 ± 8.4 1.7 ± 0.1
50% Ethanolic extract 40.4 ± 3.9** 4.0 ± 0.0 34.8 ± 1.3# 1.7 ± 0.3
n-Butanol fraction 2.7 ± 0.6** 3.4 ± 0.3 8.8 ± 0.6# 1.8 ± 0.5
*Various plant extracts/n-butanol fraction were used at 100 μg/ml.
**p < 0.001 as compared to IL-8 concentration in the control group.
#p < 0.001 as compared to IL-6 concentration in the control group.There was no cytotoxicity observed by all the extracts/
fraction up to 100 μg/ml and none of them led to a signifi-
cantly enhanced secretion of pro-inflammatory cytokines
as an effect to VK2/E6E7 cells treatment. Since both IL-6
and IL-8 are associated with an increased HIV-1
replication, this could be an added advantage of the active
n-butanol fraction of A. catechu as an anti-HIV-1 mi-
crobicide [35,36]. The decrease in secretion of pro-
inflammatory cytokines, IL-6 as well as IL-8, may be
due to the catechins that are present in abundance in
the stem bark of A. catechu and have been reported
previously for their anti-inflammatory properties [15].
Preclinical safety investigations should also comprise
evaluation of interference with epithelial integrity.
Maintenance of an intact as well as polarized monolayer
in presence of a potential microbicide candidate is an
important factor to be considered as any damage in epi-
thelial layer may allow infectious virus to reach the host
target cells [22,23]. Observed transient decrease in TER
of CaCo-2 cells in presence of n-butanol fraction, may
be due to the differential sensitivity of CaCo-2 cells
versus HEC-1A cells as shown previously with tenofovir
gel [37]. With no deleterious effect on the epithelial bar-
rier layer, the extracts as well as n-butanol fraction from
A. catechu appears to be safe and suggests their utility
as microbicide candidate.
Materials and methods
Collection of plant material
A. catechu plant material was collected three times
from Balrampur, Uttar Pradesh, India. The voucher
specimen (accession number NBRH-04) has been sub-
mitted to Herbarium of National Botanical Research
Institute, Lucknow, India.
Extraction and solvent fractionation of plant material
Air and shed dried stem bark from A. catechu was grinded
and strained through 30 mesh (0.5 mm). The finely
grinded stem bark (100 gm) was treated with 500 ml
MilliQ water at 60-75°C for 6–8 h. This process was
repeated three more times. The hot water extract was
filtered through Whatman filter paper number 1. The
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Figure 8 Effect of n-butanol fraction of Acacia catechu on transepithelial resistance on monolayer of epithelial cells. A) The effect of
n-butanol fraction on Caco-2 epithelial cells monolayer integrity. Plant n-butanol fraction/Nonoxynol-9 (N-9) was added to the apical chamber at
t = 0 and transepithelial resistance (TER) readings were measured at 0.5, 1, 2, 4, 8 and 24 h. As toxicity control, N-9 gel (1:50 dilution ~ 0.6 mg/ml)
was added to the indicated well. B) The effect of the n-butanol fraction on TER of HEC-1A cells. Values are expressed as mean ± SE of 2 different
experiments performed in duplicates.
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http://www.virologyj.com/content/10/1/309combined filtrate (1300 ml) was distilled at 45-50°C under
vacuum to concentrate the extract to 300 ml. The extract
was then lyophilized at −20 to −40°C to afford 7-9% dry
extract. To prepare 50% ethanolic extract, finely grinded
plant material (100 gm) was charged in a percolator and
treated with ethanol: water (1:1 v/v; 500 ml) at 25-30°C
overnight. The marc was extracted thrice by cold perco-
lation (1:1 v/v; 500 ml×3) and the combined percolate
(1000 ml) was evaporated at 40-45°C under vacuum to
obtain 7-9% dry extract. The dried 50% ethanolic stem
bark extract (10 gm) was suspended in 100 ml petroleum
ether, followed by stirring at 10–20 rpm at 30-40°C for
30–60 min and was subsequently left overnight at room
temperature (25-30°C). Petroleum ether soluble fraction
was collected after filtration. The marc (residual petro-
leum ether insoluble extract) was treated three more times
with the petroleum ether as above, to collect the total
petroleum ether soluble fraction. It was concentrated at
30-40°C and finally dried under vacuum to collect 7-9%
of dried petroleum ether soluble fraction. The residualpetroleum ether insoluble extract, left after extraction, was
air dried for 20–30 h. It was then suspended in 100 ml of
chloroform followed by stirring at 10–20 rpm at 30-40°C
for 30–60 min and was left overnight at room tem-
perature. The clear chloroform soluble fraction was col-
lected after filtration through Whatman filter paper
number 1. The residual chloroform insoluble extract was
treated thrice with the chloroform as above, to collect the
total chloroform soluble fraction. It was concentrated at
35-45°C and finally vacuum dried to collect 17-20% of
dried chloroform soluble fraction. The residual chloro-
form insoluble extract was air dried for 20–30 h and
treated in a similar way with n-butanol to prepare the
n-butanol soluble fraction.
Isolation of compounds
The 50% ethanolic extract (10 g) from stem bark was
chromatographed on silica gel (100–200 mesh, Merck,
Darmstadt, Germany) using petroleum ether, ethyl acetate
and methanol as eluants. The ethyl acetate and methanol
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http://www.virologyj.com/content/10/1/309soluble fractions (95:5 to 80:20 v/v) afforded 5 com-
pounds, which were further purified by preparative Thin
Layer Chromatography (TLC) using different solvents.
These compounds were identified by direct comparison
with the spectroscopic data (NMR and MS) of authentic
samples, procured from MP Biomedicals, Ohio, Solon,
USA; Life Biochem Technologies Pvt. Ltd., New Delhi,
India and Sigma Aldrich Inc., St Louis, MO, USA.
Cells
TZM-bl cells [HeLa cell line expressing high levels of
CD4, HIV-1 co-receptors CCR5 & CXCR4 with β-
galactosidase and luciferase as reporter genes under
HIV-1 LTR promoter; 38], HEC-1A [American Type
Culture Collection, Manassas, VA, USA; an endometrial
adenocarcinoma cell line; 39] and HEK-293 T cells were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma-Aldrich Inc.) supplemented with 10%
fetal bovine serum (FBS; Biological Industries, Kibbutz
beitHaemek, Israel) and an antibiotic-antimycotic cock-
tail [Penicillin (100 units/ml), Streptomycin (100 μg/ml)
and Amphotericin B (250 ng/ml); Pen-Strep-Ampho sol,
Biological Industries]. Peripheral blood lymphocytes
(PBLs; obtained through IRB-approved protocol) and
Caco-2 cells (American Type Culture Collection; a hu-
man epithelial colorectal adenocarcinoma cell line) were
cultured in RPMI supplemented with 10% FBS and
antibiotic-antimycotic cocktail as mentioned above. An
immortalized cell line, Vk2/E6E7 (derived from the
normal human vaginal mucosa), a generous gift from
Dr. Raina Fichorova (Brigham and Women’s Hospital,
Boston, MA, USA) was cultured in Keratinocyte serum-
free medium (ker-sfm; Gibco- Invitrogen, Carlsbad, CA,
USA) supplemented with bovine pituitary extract and
epidermal growth factor [EGF; Gibco-Invitrogen; 40].
Virus generation
HIV-1NL4.3 (CXCR4 tropic virus) was prepared by trans-
fecting HEK-293 T cells with proviral plasmid DNA
clone pNL4.3 (AIDS Research and Reference Reagent
Program [ARRRP], Division of AIDS, National Institute
of Allergy and Infectious Diseases, USA) using CaPO4.
The medium was changed 24 h post-transfection and
the supernatant was harvested after 48 h of incubation
and frozen at −80°C. The concentration of virus stock
was determined by the HIV-1 p24 Antigen Capture
Assay ELISA (SAIC-Frederick Inc., NCI-Frederick, USA)
and by determining the infectious titer using TZM-bl
cells. Known inhibitors against HIV-1 infection, Azido-
thymidine (AZT; reverse transcriptase inhibitor; Sigma-
Aldrich Inc.), Saquinavir (a protease inhibitor; ARRRP),
Nevirapine (RT inhibitor; ARRRP) and Bicyclam (CXCR4
fusion inhibitor; ARRRP) were used as experimental
controls.Anti-HIV-1 activity study
Cell-free virus based assay using TZM-bl cells
TZM-bl cells (4.0×104/well) were seeded in 24-well plate
and cultured overnight. In separate vials, HIV-1NL4.3 at a
multiplicity of infection (MOI) of 0.05 whereas HIV-1BaL
at TCID50, were treated with extracts/fractions or solvents
used to prepare above extracts/fractions for 1 h at 37°C.
Subsequently, pretreated viruses were added in duplicate
to TZM-bl cells and cultured for 4 h. The cells were
washed once with cold 50 mM PBS, pH-7.4 to remove the
cell-free virus followed by addition of fresh culture
medium with extracts/fractions and further incubated for
48 h in humidified atmosphere of 5 CO2 at 37°C. AZT
was used as a positive reference control whereas negative
control comprised of cells without HIV-1 infection. After
incubation, cells were washed twice with PBS and lysed
with 1X lysis buffer (Promega Corporation, Madison,
USA) by freeze-thaw. The supernatant was analyzed
for luciferase activity by BrightGlo Luciferase Assay kit
(Promega Corporation) in white opti-plate and lumines-
cence was read using Fluorimeter (BMG Labtech GmbH,
Offenberg, Germany) at a spectral range of 240–740 nm.
The n-butanol fraction prepared from A. catechu was also
evaluated for its efficacy against CCR5-tropic clinical iso-
lates using the same protocol except that the culture
medium in addition contain DEAE-dextran hydrochloride
(50 μg/ml, Sigma-Aldrich Inc).
Cell-associated virus based assay using peripheral blood
lymphocytes (PBLs)
Experiments using human blood cells were carried out
under informed consent and following the clearance
from the Institutional Bio-safety and Human Ethical
Committee. Blood (5 ml) was taken from healthy HIV-1
seronegative donors and lymphocytes were isolated
using Ficoll density gradient method. Cells (2.0×106
cells/ml) were stimulated with phytohemagglutinin
(PHA-P; Sigma-Aldrich Inc.) at 3 μg/ml for 3 days. After
stimulation, cells were washed twice with PBS. PBLs
were infected with HIV-1NL4.3 at an MOI of 0.05, in
presence of IL-2 (10 U/ml) for 4 h. Cells were washed
twice with plain medium to remove the unbound virus
and seeded in 96-well plate (5.0×104/well/200 μl) in
RPMI medium supplemented with 10% FBS and recom-
binant human IL-2 (10 U/ml). Plate was further incu-
bated at 37°C, 5% CO2 after adding the n-butanol
fraction at varying concentrations to the wells. Cell cul-
ture supernatant was collected on 5th day for p24 ana-
lysis. The culture supernatant (100 μl) was further used
for infection of TZM-bl cells for 4 h, and luciferase ex-
pression was estimated after 48 h as described above to
validate the infectivity of virion particles released by
PBLs as an effect of treatment with n-butanol fraction
of A. catechu.
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Virus in the culture supernatant of n-butanol fraction/
AZT treated human PBLs was quantitated by p24
estimation using an ELISA kit (SAIC-Frederick Inc.,
NCI-Frederick, USA; XpressBio, Life Science Products,
MD, USA), following the instructions of the manufac-
turer. Virus load in uninfected cells was used as negative
control whereas virus load in solvent treated infected
cells was the virus control. Test control includes virus
load in infected PBLs treated with either n-butanol
fraction/AZT.
Study of mechanism of inhibition of HIV-1 infection
HIV-1 entry assay
TZM-bl cells (4 × 104) were pretreated with or without
plant n-butanol fraction at 37°C for 1 h before being
infected at an MOI of 0.05. Bicyclam was used as a refe-
rence control. The infected cells were trypsinized and
washed with PBS to remove the unattached virus and cul-
tured in fresh medium. After 48 h incubation, percent in-
hibition in HIV-1 infection was determined as described.
Env-dependent fusion assay
This bioassay allows testing for inhibitors capable of
interfering with the CD4-Env interaction [41]. It em-
ploys HL2/3 cell line that express Gag, Env, Tat, Rev,
and Nef, but not reverse transcriptase and secretes the
env protein in the medium. HL2/3 cells (2.5 × 104)
were treated with the butanol fraction (25 μg/ml) in
separate vials for 30 min and washed thereafter. Pre-
treated HL2/3 cells were then incubated with untreated
TZM-bl cells (2.5 × 104) for another 30 min. Cells were
then seeded in a 24-well plate (2.5 × 104 of each cell
type/well) and incubated at 37°C in 5% CO2. Fusion was
readily detected microscopically after 8 h incubation. As a
result of fusion, the luciferase as well as β-galactosidase
gene under the LTR promoter gets expressed in the
reporter TZM-bl cells. For quantitation of luciferase
expression, the cells were harvested after 36 to 48 h, lysed
in 100 μl of 1X lysis buffer and luciferase activity was esti-
mated as described above.
Alu-HIV-1 integration PCR
To examine HIV-1 DNA integration, semi-quantitative
nested Alu-LTR PCR was done as described previously
[31,42]. The following primers were used for the first
round of amplification:
Alu-gag (Alu Forward):
5′GCCTCCCAAAGTGCTGGGATTACAG3′
Alu-gag (gag Reverse):
5′GTTCCTGCTATGTCACTTCC-3′
The primers for second round were;RU5 (R forward):
5′-TTAAGCCTCAATAAAGCTTGC C-3′
RU5 (U5 Reverse):
5′-GTTCGGGCGCCACTGCTAGA-3′
Genomic DNA (200 ng) prepared from TZM-bl cells
infected with HIV-1NL4.3 in presence or absence of n-
butanol fraction prepared from A. catechu or Raltegravir
(integrase inhibitor) was used as a template for amplifi-
cation with the first set of Alu-HIV-1 PCR primers in a
25 μl PCR mix. Amplification cycles were 95°C for
5 min followed by 39 cycles of 95°C for 15 sec, 50°C for
15 sec, and 72°C for 3.5 min. In the nested step, 4.0 μl of
the first PCR product was used as a template in a 25 μl
reaction volume and was amplified for 35 cycles using a
similar PCR protocol as noted earlier. GAPDH was amp-
lified as an internal control from 200 ng genomic DNA
as a template using the cycle program as 95°C for
10 min followed by 39 cycles of denaturation at 95°C for
30 sec, 60°C for 40 sec, and 72°C for 40 sec. The ampli-
fied PCR products were resolved on 2% agarose gel and
visualized by ethidium bromide staining.
HIV-1 reverse transcriptase (RT), protease and integrase
inhibition assays
The inhibitory activity of the active n-butanol fraction of
A. catechu on HIV-1 RT, protease and integrase was
determined as per the manual’s instructions of the re-
spective kits (RT assay kit from Roche Applied Sciences,
Mannheim, Germany; Protease assay kit from Anaspec,
CA, USA and Integrase Assay kit from XpressBio, Life
Science Products, MD, USA; http://www.xpressbio.com/
sites/default/files/EZ-1700hiv_integrase_wildtype_kit%20v
%203.0_pi_061411_0.pdf).
Tat-inhibitor assay
TZM-bl cells (4.0×104/well) were seeded in 24-well plate
and cultured overnight. The cells were transfected with
pTat (0.1 μg/well; ARRRP, USA) using Lipofectamine re-
agent (Invitrogen) according to the manufacturer’s in-
structions. After 4 h of transfection, cells were treated
with the active plant fraction at 37°C. Forty-eight hours
post-treatment, luciferase activity was measured as des-
cribed above.
Quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR)
Total RNA was isolated using the Tri reagent (Sigma
Aldrich Inc.) following the standard protocol from TZM-bl
cells transfected with pTat as described above. The iso-
lated RNA (1 μg) was used to prepare the cDNA using
random hexamers, dNTP mixture, RT buffer and Super-
script III reverse transcriptase following the manufac-
turers’ protocol. The expression level of mRNA has been
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primers. The forward and reverse primers used were 5′
ACCGCAAGTGGGGCTTCTGC 3′ and 5′ CGTGGCC
AAACTCGTGGGCT 3′, respectively. The PCR parame-
ters used were initial denaturation for 10 min at 95°C, and
40 cycles of 95°C for 15 s followed by amplification for
1 min at 62°C. Average threshold cycle (Ct) values for 18S
rRNA (run in parallel reactions to the genes of interest)
were used to normalize the average Ct values of the gene
of interest. These values were used to calculate the average
for each group from different experiments and the relative
δCt was used to determine the change in the expression
between the groups.
Tat-electrophoretic mobility shift assay (EMSA)
Tat-EMSA was performed using TAT-EMSA kit (Panomics,
Inc., Redwood City, CA, USA), following user’s manual.
Biotin labelled transactivation factor (TF, transactivating
regulatory protein) and cold (unlabelled) TF DNA probes
were provided by the manufacturer [32]. Nuclear extracts
that served as a source of Tat protein were prepared from
transfected TZM-bl cells. TZM-bl cells were transfected
with pTat as described above. Cells were washed twice
with PBS and nuclear extracts were prepared using NE-
PER Nuclear and Cytoplasmic Extraction Kit (Pierce,
Rockford, IL, USA). Protein concentration was deter-
mined by the BCA protein estimation kit (Pierce). Briefly,
TF DNA probe was incubated with nuclear extract (4 μg)
for 30 min either in the presence of n-butanol fraction
(50 μg/ml) of A. catechu or cold TF DNA probe provided
in the kit. To determine the mobility shift of the DNA
probe in presence or absence of plant fraction/cold DNA
probe, the samples were run in a non-denaturing poly-
acrylamide gel, as suggested by the manufacturer at 120 V
until the dye had migrated 2/3 of the way down the gel.
The gel was then transferred to a nylon membrane, UV-
cross linked and biotin-labelled DNA was detected by
chemiluminescence.
Safety studies of plant extracts and n-butanol fraction
Cytotoxicity assessment by MTT assay
Cytotoxicity of extracts/fractions was assessed using
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide; Sigma-Aldrich Inc.] assay [43]. Briefly,
TZM-bl cells (6.0 × 103/well/100 μl) were seeded in
a 96-well culture plate (Greiner Bio-One, GmbH,
Frickenhausen, Germany) and grown overnight at 37°C
in a humidified atmosphere of 5% CO2. Next day, cul-
ture medium with increasing concentrations of various
extracts/fractions was added in duplicate and further incu-
bated for 48 h. Appropriate solvents, used to prepare vari-
ous extracts/fractions were included as negative controls.
After incubation, 20 μl of MTT reagent (5 mg/ml) was
added per well and incubated at 37°C for 3 h followed byaddition of MTT solvent (100 μl/well; 20% SDS and 50%
dimethyl formamide in 50 mM PBS). The absorbance
(OD) was read at 570 nm with reference filter at 690 nm.
Cell viability was calculated using the equation,
% Viability ¼ ODExtract=fraction treated cells=ODUntreated cells
 
 100
Estimation of pro-inflammatory cytokines secreted by
human cervico-vaginal keratinocytes
To study, if plant extracts/fractions induce epithelial
toxicity and inflammation, their impact on a human
cervico-vaginal keratinocyte cell line (Vk2/E6E7) viabi-
lity and analysis of pro-inflammatory cytokines secretion
was done. Cervico-vaginal Vk2/E6E7 cells (6.0 × 103/
well) were seeded in 96-well culture plate and incubated
in humidified atmosphere of 5% CO2 at 37°C for 24 h.
After incubation, cells were treated with varying concen-
trations of plant extracts for 24 h and culture super-
natant was collected for various cytokines quantitation
using BDTM Cytometric Bead Array kit (BD FACSCanto
Flow Cytometer; BD Biosciences Pharmigen, San Diego,
CA, USA). The kit allowed simultaneous quantification
of interleukin-10 (IL-10), IL-12 (p70), IL-1β, IL-6, IL-8
and tumor necrosis factor (TNF). The cytokine bead
assay was performed according to the manufacturer’s
specifications and data analysis was done using BD
FACSDiva software. In addition, Vk2/E6E7 cells viability
after 24 h treatment with test extracts and n-butanol
fraction was also determined by MTT assay as described
above.
Transepithelial resistance (TER) measurement
Epithelial cells monolayer integrity, lining the repro-
ductive tract is critical for the prevention of sexual
transmission of HIV-1. Transepithelial resistance (TER),
a measure of epithelial integrity, was performed. Caco-2
/HEC-1A cells (5.0 × 105/well) were grown in appro-
priate medium (1 ml) in the apical chamber of transwell
plates and culture medium (1.5 ml) was dispensed in
the basolateral compartment of each well. The cells
were allowed to grow for 36–48 h in 5% CO2 at 37°C
and assessed for formation of monolayer by measuring
TER. Resistance was measured using Millicell–ERS
voltmeter (EMD Millipore Corporation, Billerica, MA,
USA) each day until resistance reached plateau. After
formation of monolayer, the plant n-butanol fraction
(50 μg/ml) was added in the culture medium and was
further incubated in humidified atmosphere of 5% CO2
at 37°C. Resistance was measured at 30 min, 1, 2, 4, 8
and 24 h after addition of either n-butanol fraction from
A. catechu or nonoxynol-9.
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Percent inhibition was calculated from luciferase/p24
content, utilizing the following formula:
Inhibition %ð Þ Virus control−Test sample
Virus control−Mock infected
 
 100
Statistical analysis
All studies were performed at least three times except
where noted in the figures legend. Means and their stand-
ard errors are shown. Analyses of concentration-response
data were performed by the use of nonlinear curve-fitting
program Prism to determine CC50 and IC50 values. Stu-
dent’s t-test was used for quantitative variables for com-
parison between the different groups.
Conclusion
In conclusion, the extracts prepared from the stem bark of
A. catechu exhibited potent anti-HIV-1 effect as demon-
strated using different in vitro assays including human
peripheral blood lymphocytes. However, the active com-
ponents responsible for the activity are yet to be explored.
The suppression of HIV-1 infection may be, in part due to
its inhibitory effect on HIV-1 protease and partly due to
the interference in interaction of viral Tat protein to the
HIV-1 promoter sequence of LTR, which is also reflected
by the expression of gene (luciferase) that is under the
control of Tat-LTR mediated transactivation. Initial safety
studies of the active n-butanol fraction from 50% ethanolic
extract using vaginal keratinocytes for pro-inflammatory
cytokines secretion and dual chamber model for epithelial
toxicity indicates that the stem bark extract of the plant
have the potential to be developed as an anti-HIV-1 mi-
crobicide candidate. Multiple mode of action of this plant
has an added advantage and suggests that further safety
and efficacy studies using in vivo models are needed.
Several attempts have been made at screening numerous
traditional plants as medicines in search for plant based
anti-HIV-1 agents. However, this is the first report for
investigation of A. catechu stem bark extracts for its anti-
HIV-1 activity, where we showed its in vitro anti-HIV-1
property through the inhibition of both HIV-1 protease
and LTR-Tat protein interaction. The active extracts,
n-butanol fraction and catechins being less toxic confirm
the specific inhibition against HIV-1 infection. In the stu-
dies done by Marquez et al., [44], anti-viral compounds
derived from plants that interfere with HIV-1 LTR pro-
moter regulatory proteins are not likely to generate drug-
resistant HIV-1 strains, hence suggesting the important
role of this plant as a traditional medicine. Further studies
to identify the active constituents from A. catechu respon-
sible for anti-HIV-1 activity are in progress.Additional files
Additional file 1: Figure S1. HPLC profiles of extracts from stem bark
of A. catechu. X-axis represents time and Y-axis represents voltage.
Solvent used was: Acetonitrile: H2O (18: 82 v/v; 0.5% acetic acid); at
280 nm; a) 50% Ethanolic extract; b) Aqueous extract.
Additional file 2: Figure S2. HPLC of fractions of 50% ethanolic stem
bark of A. catechu. X-axis represents time (in mins), whereas Y-axis
represents the absorbance at 280 nm; Solvent: Acetonitrile: H2O (18: 82 v/
v; 0.5% acetic acid); a) Petroleum ether soluble fraction; b) Chloroform
soluble fraction; c) n-Butanol soluble fraction.
Additional file 3: Figure S3. Cytotoxicity of n-butanol fraction on PBLs.
The figure shows the cytotoxicity of n-butanol fraction from A. catechu
on HIV-1NL4.3 infected PBLs after 5 days treatment determined by MTT
assay as described in Materials and Methods. Y-axis shows the percent
viability of cells.
Additional file 4: Figure S4. Mechanism of inhibition by n-butanol
fraction at pre-integration steps of HIV-1. A) Env-mediated cell based
fusion assay. A cell-based fusion assay was used to mimic the gp120-CD4
mediated fusion of the viral and host cell membranes. HL2/3 cells were
pre-incubated with n-butanol fraction from A. catechu (25 μg/ml) prior to
incubation with untreated TZM-bl cells for fusion. Bicyclam (1 μg/ml) was
used as positive reference control. B) The effect of n-butanol fraction of
A. catechu against HIV-1 Reverse Transcriptase (RT) activity at 50 ug/ml as
compared with the reference control, Nevirapine (1 μM). Y-axis represents
the percent inhibition. C) The inhibitory activity of n-butanol fraction on
HIV-1 integrase activity at 50 μg/ml and sodium azide (1.5%) used as
positive control. Y-axis represents the percent inhibition in HIV-1
integrase activity. Values are expressed as mean ± SE of 2 different
experiments performed in duplicates.Abbreviations
HIV-1: Human immunodeficiency virus-1; HPLC: High performance liquid
chromatography; LTR: Long terminal repeat; IL: Interleukin; RT: Reverse
transcriptase; TLC: Thin layer chromatography; MOI: Multiplicity of infection.
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